SilicoGenesis

SilicoGenesis is revolutionizing the field of antibody and biologic design, discovery, and optimization, positioning itself as a leader in the industry. Our cutting-edge expertise and advanced technologies empower pharmaceutical and biotech companies to expedite and scale up the discovery and optimization of antibody lead molecules. Through our state-of-the-art AI/ML algorithms, in-silico pipelines, and collaborative expert team, we rapidly develop innovative therapeutic lead molecules. Our comprehensive suite of solutions in the drug discovery pipeline encompasses: * Precise 3D modeling of protein structures. * Accurate prediction of paratope and epitope residues. * Thorough characterization and modeling of protein-protein interactions. * Enhancement of binding affinity and mutagenesis studies. * Cross-species reactivity analysis. * Expert humanization of antibody candidates. * Rigorous assessment of developability liabilities. SilicoGenesis has established a strong track record of successful collaborations with numerous pharmaceutical companies, biotech firms, and academic institutions across diverse projects. We are committed to supporting your specific needs and objectives. To learn more about our transformative capabilities, please visit our website at www.silicogenesis.com.

Website

https://www.silicogenesis.com

External link for SilicoGenesis

Industry

Biotechnology Research

Company size

2-10 employees

Headquarters

Leuven, Flemish Region

Type

Partnership

Founded

2021

Specialties

Bioinformatics, Computational Biology, Machine Learning, Protein Biochemistry, Antibody Engineering, Artificial Intelligence, Structural Biology, Drug Discovery, Protein Engineering, and Nanobody Engineering